PUBLISHER: The Business Research Company | PRODUCT CODE: 1946943
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946943
Percutaneous mechanical circulatory support (pMCS) devices are minimally invasive systems designed to temporarily assist or fully replace the heart's pumping function. These devices are inserted through a catheter into blood vessels, typically via the femoral artery, and positioned within the heart to provide mechanical support during acute heart failure, cardiogenic shock, or high-risk cardiac interventions.
The main types of percutaneous mechanical circulatory support devices include intra-aortic balloon pumps, Impella devices, extracorporeal membrane oxygenation, TandemHeart, and other variations. An intra-aortic balloon pump (IABP) is a device that helps the heart pump blood by inserting a balloon catheter into the aorta, the large artery carrying blood from the heart. It is used to support patients with severe cardiac conditions such as cardiogenic shock, acute myocardial infarction, and heart failure, among others. IABPs are utilized by various end users, including hospitals, ambulatory surgical centers, and other healthcare settings.
Tariffs are impacting the pMCS devices market by increasing costs of precision pumps, catheters, and electronic monitoring components. Advanced systems such as ECMO and Impella devices are most affected, particularly in regions reliant on imported components. However, tariffs have encouraged domestic manufacturing, supply chain diversification, and innovation in cost-efficient circulatory support systems.
The percutaneous mechanical circulatory support devices market research report is one of a series of new reports from The Business Research Company that provides percutaneous mechanical circulatory support devices market statistics, including percutaneous mechanical circulatory support devices industry global market size, regional shares, competitors with a percutaneous mechanical circulatory support devices market share, detailed percutaneous mechanical circulatory support devices market segments, market trends and opportunities, and any further data you may need to thrive in the percutaneous mechanical circulatory support devices industry. This percutaneous mechanical circulatory support devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The percutaneous mechanical circulatory support devices market size has grown strongly in recent years. It will grow from $2.46 billion in 2025 to $2.7 billion in 2026 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to rising cardiovascular disease burden, increasing cardiogenic shock cases, adoption of minimally invasive procedures, ICU care expansion, aging population.
The percutaneous mechanical circulatory support devices market size is expected to see strong growth in the next few years. It will grow to $3.87 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to AI-assisted cardiac monitoring, growth in complex cardiac interventions, expansion of cath lab procedures, demand for temporary heart support, advanced pump technologies. Major trends in the forecast period include minimally invasive cardiac support, short-term hemodynamic assistance, high-risk pci support devices, rapid deployment cardiac systems, enhanced patient safety designs.
The rising incidence of cardiovascular diseases is anticipated to drive the growth of the percutaneous mechanical circulatory support devices market in the coming years. Cardiovascular diseases (CVDs) encompass a range of conditions that affect the heart and blood vessels, including coronary artery disease, heart attacks, heart failure, stroke, and hypertension. The growing incidence of cardiovascular diseases is driven by factors such as an aging population, unhealthy lifestyle habits, obesity, high blood pressure, and genetic susceptibility. Percutaneous mechanical circulatory support devices are utilized in the management of cardiovascular diseases to enhance cardiac performance, reduce stress on the heart, and aid recovery in critical cardiac conditions. For example, in October 2024, according to the Centers for Disease Control and Prevention, a US-based public health institute, in 2023, approximately 1 in every 6 deaths from cardiovascular diseases occurred among adults younger than 65 years, and a total of 919,032 deaths were attributed to cardiovascular disease, accounting for 1 in every 3 deaths. Therefore, the increasing incidence of cardiovascular diseases is fueling the growth of the percutaneous mechanical circulatory support (MCS) devices market.
Leading companies in the percutaneous mechanical circulatory support devices market are concentrating on developing advanced solutions, such as intra-aortic axial-flow devices, to improve patient outcomes and reduce surgical risks. An intra-aortic axial-flow device is a type of percutaneous mechanical circulatory support (MCS) device designed to support heart function by increasing blood flow from the left ventricle to the aorta. For example, in February 2023, Procyrion, Inc., a US-based medical device company, announced the successful first-in-human use of its Aortix pump. This innovative device aims to prevent acute kidney injury (AKI) in patients undergoing cardiac surgery. The Aortix pump, delivered via a catheter into the descending thoracic aorta, enhances renal perfusion while reducing the heart's workload during surgery. By improving both renal and systemic perfusion and decreasing heart strain, the device is particularly beneficial for patients with impaired left ventricular function and renal issues. Capable of providing up to 5.0 liters of flow per minute, the Aortix pump is intended for short-term use during procedures such as percutaneous coronary interventions (PCI).
In April 2023, Abbott Laboratories, a US-based diversified healthcare and medical device company, acquired Cardiovascular Systems, Inc. (CSI) in a transaction valued at approximately US$890 million. Through this acquisition, Abbott seeks to strengthen its vascular portfolio by incorporating CSI's leading orbital atherectomy systems used in the treatment of complex peripheral and coronary artery disease, as well as by gaining access to an early-stage pipeline of complementary vascular intervention technologies, including catheter-based solutions for percutaneous mechanical circulatory support in high-risk coronary procedures. Cardiovascular Systems, Inc. is a US-based medical device company dedicated to the development and commercialization of innovative atherectomy systems and related interventional technologies for treating peripheral and coronary artery disease.
Major companies operating in the percutaneous mechanical circulatory support devices market are Abbott Laboratories, Medtronic Plc, Getinge AB, Teleflex Incorporated, Biotronik, Abiomed Inc., LivaNova Plc, Bioventrix, Berlin Heart, Eurosets, Magenta Medical Ltd, SynCardia Systems LLC, CardiacAssist Inc., Jarvik Heart Inc., Procyrion, BiVACOR Inc., CardioBridge GmbH and Company, Circulite Medical Inc., NovaPump GmbH, Supira Medical Inc., Pulsatile Technologies Inc.
North America was the largest region in the percutaneous mechanical circulatory support devices market in 2025. The regions covered in the percutaneous mechanical circulatory support devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the percutaneous mechanical circulatory support devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The percutaneous mechanical circulatory support (MCS) devices market consists of sales of left ventricular assist devices, centrifugal flow pumps, and percutaneous right ventricular assist devices. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Percutaneous Mechanical Circulatory Support Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses percutaneous mechanical circulatory support devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for percutaneous mechanical circulatory support devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The percutaneous mechanical circulatory support devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.